Related Experiment Video
Updated: May 3, 2026
Software-Assisted Quantitative Measurement of Osteoarthritic Subchondral Bone Thickness
Published on: March 18, 2022
Mechanistic study of COL6A1-mediated subchondral bone remodeling in osteoarthritis via the EPAC/RAP1 axis
Qu Xu1, Gangning Feng1,2, Zhiqun Tang1,2
1The Third Ward of Orthopaedic Department, General Hospital of Ningxia Medical University, Yinchuan, Ningxia Hui Autonomous Region, China.
Abstract:
This study aimed to identify key molecular targets that drive osteoclasts (OCs) influenced progression of osteoarthritis (OA) and to explore their mechanisms influencing OCs differentiation and OA progression. We conducted weighted gene co-expression network analysis (WGCNA) and differential expression analysis using OA datasets from the GEO database, cross-referencing these findings with OCs differentiation datasets, ultimately identifying COL6A1 as a hub gene. Validation results indicated that COL6A1 expression was increased during both OA progression and OCs differentiation. Immune-related analysis indicates that the expression level of COL6A1 can influence the immune microenvironment in the subchondral bone of OA. Subsequent in vitro perturbation and rescue experiments demonstrated that COL6A1 enhances OCs differentiation and formation by activating the EPAC/RAP1 signaling axis. In vivo experiments further confirmed that COL6A1 knockdown reduced OC-mediated subchondral bone remodeling and slowed OA progression in DMM mouse models. Additionally, the molecular docking results suggest that ingenol-mebutate is a potential functional inhibitor of COL6A1. In summary, this study indicates that COL6A1 promotes the differentiation and formation of OCs by activating the EPAC/RAP1 signaling axis. Targeted blockade of COL6A1 can alleviate subchondral bone remodeling and OA progression in DMM model mice. Ingenol mebutate is a potential therapeutic drug.
Insights
Collagen type VI alpha 1 chain (COL6A1) drives osteoarthritis progression by promoting osteoclast differentiation via the EPAC/RAP1 pathway. Blocking COL6A1 may offer a therapeutic strategy for osteoarthritis.
Area of Science:
- Biochemistry
- Molecular Biology
- Immunology
Background:
- Osteoarthritis (OA) is a degenerative joint disease characterized by cartilage breakdown and subchondral bone changes.
- Osteoclasts (OCs) play a critical role in OA pathogenesis, particularly in subchondral bone remodeling.
- Identifying molecular targets that regulate OC activity is crucial for developing effective OA therapies.
Purpose of the Study:
- To identify key molecular targets driving osteoclast-mediated OA progression.
- To elucidate the mechanisms by which these targets influence osteoclast differentiation and OA.
- To explore potential therapeutic interventions targeting identified molecular pathways.
Main Methods:
- Weighted gene co-expression network analysis (WGCNA) and differential expression analysis on OA datasets.
- Cross-referencing with osteoclast differentiation datasets to identify hub genes.
- In vitro perturbation, rescue experiments, and in vivo studies using DMM mouse models.
- Molecular docking for potential drug candidate identification.
Main Results:
- COL6A1 was identified as a key hub gene, with its expression upregulated in OA progression and OC differentiation.
- COL6A1 enhances OC differentiation and formation by activating the EPAC/RAP1 signaling axis.
- COL6A1 knockdown reduced OC-mediated subchondral bone remodeling and slowed OA progression in vivo.
- Ingenol mebutate was identified as a potential inhibitor of COL6A1.
Conclusions:
- COL6A1 is a critical mediator of osteoclast differentiation and OA progression through the EPAC/RAP1 pathway.
- Targeted blockade of COL6A1 demonstrates therapeutic potential for mitigating OA.
- Ingenol mebutate represents a promising therapeutic agent for OA treatment.
